ALBANY, N.Y., Dec. 17, 2012 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the appointment of George W. Bourne as Senior Vice President and Chief Technology & Operations Officer. Previously Mr. Bourne was Senior Vice President and Chief Technology Officer for the Company, joining in May, 2012. In his new role, Mr. Bourne will oversee Research and Development, Sustaining Engineering, Operations and Clinical Affairs and assumes the responsibilities of Scott Etlinger, Senior Vice President, Global Operations, who will be leaving the company.
"George Bourne has quickly made a very positive contribution to AngioDynamics since joining our team earlier this year," said Joseph M. DeVivo, President & CEO. "George's deep commitment to operational excellence, combined with more than 25 years of experience in operations and R&D at global medical device companies, provide us with a very capable and seasoned executive to lead our R&D and operations teams as we implement our growth strategies."
Previous to joining AngioDynamics, Mr. Bourne served as VP of R&D at Hologic, and before this served as Senior Vice President of R&D and Clinical Affairs for Navilyst Medical from its formation in early 2008 until November 2011. His tenure was defined by focused portfolio development and the commercialization of new products. He also served 10 years at Boston Scientific as Vice President, R&D, of the Urology, Meditech and Oncology business units and then as Group Vice President, R&D, for the endosurgery business group. Mr. Bourne earned his Bachelor of Science in Biological Science and Master of Science in Plastics Engineering from the University of Lowell, in addition to his MBA from Rivier College in Nashua, N.H. He also served in leadership positions at Baxter Healthcare, Allegiance Healthcare and C.R. Bard.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts